369 related articles for article (PubMed ID: 33512768)
1. Prognostic impact of maximum standardized uptake value on
Qiu X; Liang H; Zhong W; Zhao J; Chen M; Zhu Z; Xu Y; Wang M
Thorac Cancer; 2021 Mar; 12(6):845-853. PubMed ID: 33512768
[TBL] [Abstract][Full Text] [Related]
2. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
[TBL] [Abstract][Full Text] [Related]
3. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
[TBL] [Abstract][Full Text] [Related]
6. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.
Aragaki M; Kato T; Fujiwara-Kuroda A; Hida Y; Kaga K; Wakasa S
J Cardiothorac Surg; 2020 Aug; 15(1):229. PubMed ID: 32859238
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
8. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
9. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
Zhai X; Guo Y; Qian X
Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of
Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
Lee JW; Na JO; Kang DY; Lee SY; Lee SM
Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
[TBL] [Abstract][Full Text] [Related]
12. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic ability of
Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.
Tong AN; Han SR; Yan P; Gong H; Zhao H; Yao H; Wang YM
Med Oncol; 2014 Jan; 31(1):780. PubMed ID: 24326983
[TBL] [Abstract][Full Text] [Related]
17. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer.
Geredeli C; Artac M; Kocak I; Koral L; Sakin A; Altinok T; Kaya B; Karaagac M
J Cancer Res Ther; 2020; 16(4):816-821. PubMed ID: 32930124
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
